Kallyope, Inc. Overview
Pro stress-test →Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis. The company aims to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Founded in 2015 by world-renowned neuroscientists, the company is leveraging proprietary technology to develop late-stage therapeutic candidates for major unmet medical needs.
Strategic Profile
Pro stress-test →The company's lead candidate is entering pivotal studies for the acute treatment of migraine, and novel metabolism programs are set to enter clinical studies in mid-2026. The company's founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D. and Nobel laureate Richard Axel, M.D. With deep scientific expertise and experienced drug development leadership, Kallyope is positioning itself as a differentiated player in metabolic and neurological therapeutics.
Competitive Landscape
Pro stress-test →Kallyope competes in the crowded obesity and metabolic disease space dominated by GLP-1 leaders like Novo Nordisk and Eli Lilly, but differentiates through its novel gut-brain axis platform and oral formulations targeting multiple disease areas including migraine and gastrointestinal conditions. The company's approach complements rather than directly replicates existing therapies.
Industry Context
Kallyope, Inc. operates in Gut-brain axis drug discovery and development.
Key facts
Founded: 2015 · Headquarters: New York, US · Employees: 91 · Revenue: N/A · Market cap: N/A